



April 2, 2018

For Immediate Release

Reborna Biosciences, Inc.

Launch of Reborna Biosciences, Inc.

Kanagawa, Japan, 2 April 2018: Today, Reborna Biosciences, Inc. (Representative director: Koji Fuji; “Company”) is pleased to announce that the company has been started the business in Shonan Health Innovation Park (“Shonan iPark”) at Takeda Pharmaceutical Company Limited (“Takeda”).

The company, a research and development start-up focusing on the field of rare genetic diseases, is established through the Takeda Entrepreneurship Venture Program. The company contributes to the development of new therapeutic options for area of high unmet medical needs in genetic rare disease.

The technology of the company will enable low-molecular compounds to target ribonucleic acid, a method deemed impossible to achieve with existing techniques. Harnessing this technology, the company aim to provide new disease-modifying drugs for patients suffering from rare genetic diseases including spinal muscular atrophy (“SMA”) and their families in the future.

“We will contribute toward the betterment of healthcare by offering new drugs that make it possible to feel being reborn for patients who suffer from genetic rare diseases and their families using our innovative drug discovery technology,” said Koji Fuji, the Company’s founder and representative director.

For further information, please contact:

Corporate Planning Office

Reborna Biosciences, Inc.

Tel: +81-466-32-1124

Email: info@rebornabiosciences.com

Website: <http://rebornabiosciences.com>